Latest Headlines

Latest Headlines

Covance plots a deeper dive into manufacturing

Covance, now a division of LabCorp, is planning to build a second manufacturing-enabled pharmacy adjacent to one of its clinical research sites, allowing the CRO to churn out doses of investigational drugs for ongoing studies.

Covance names a new CEO as it adjusts to life with LabCorp

Covance, acquired by LabCorp for about $6 billion earlier this year, has picked former head of R&D Deborah Keller to take the reins as CEO Joseph Herring retires.

Covance and LabCorp open a new R&D center to pool their expertise

Covance, recently acquired by testing giant LabCorp, has opened a new, expanded clinical research unit in Texas, pairing space for trials alongside a planned patient-service center operated by its parent company.

Icon and Covance bet on diagnostics with a pair of cancer deals

CROs Icon and Covance signed a pair of separate partnerships in the world of cancer diagnostics, each betting that new technologies in oncology testing will increase global demand.

Covance joins trial site group to speed up R&D

Covance, now a division of LabCorp, has signed a two-year partnership with the Society for Clinical Research Sites, joining a growing list of CROs working to improve communication between sponsors and investigators.

LabCorp inks a cancer deal with Covance in mind

LabCorp, now the owner of CRO giant Covance, partnered up with Japan's Sysmex to bring in some new technology it believes will make its subsidiary more competitive in the market for oncology clinical trials.

China's Sihuan marks first U.S. patient enrollment of PhI oncology candidate

Sihuan Pharmaceutical said it has successfully enrolled the first patient in the United States for its Phase I clinical trial of Pirotinib developed by Shandong XuanZhu Pharma, a wholly owned subsidiary, working with Covance on preparation and initiation.

HK's Sihuan in partnership with Covance on drug development

Hong Kong-listed Sihuan Pharmaceutical said it has joined hands with U.S.-based Covance to develop a drug pipeline aimed at China and U.S. approvals.

Analyst casts doubt on Big Data potential of Covance-LabCorp merger

LabCorp closed its $5.7 billion takeover of Covance this week and immediately began talking up the potential for its testing data to turbocharge the CRO's clinical trial business.

LabCorp seals its $6B deal for Covance

One of the world's largest CROs is no longer an independent entity as Covance has folded into testing giant LabCorp, closing a $6 billion deal and altering the industry landscape.